

Special Issue

Innovative Vaccines and Technologies to Address Tropical Parasitic Diseases

Message from the Guest Editors

Tropical parasitic diseases significantly impact global health, particularly in endemic regions where access to prevention and treatment is limited. These infections, caused by complex eukaryotic pathogens such as *Trypanosoma cruzi*, *Leishmania spp.*, and *Plasmodium spp.*, present unique immunological and biological challenges that complicate traditional vaccine approaches. Developing safe, effective, and accessible vaccines is essential to reducing morbidity, preventing transmission, and contributing to long-term disease control and eventual elimination. This Special Issue aims to feature innovative scientific advances in vaccine research for tropical parasitic diseases. We invite original research articles and comprehensive reviews that cover topics such as antigen discovery, chimeric and multi-epitope vaccine design, novel adjuvants, immunomodulatory strategies, host-parasite interactions, and biotechnology-based delivery platforms. This Special Issue seeks to advance the field and promote the creation of next-generation vaccines with a significant global impact. We look forward to receiving your contributions.

Guest Editors

Dr. Cecilia Maria Perez Brandan

Dr. Iván Marcipar

Dr. Fernando Sanchez-Valdez

Deadline for manuscript submissions

30 May 2026



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/251880

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).